Bharat Biotech seeks DCGI nod for phase-3 study of intranasal Covid vaccine in 5-18 age group

iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase 1, 2 and 3 clinical trials with successful results, a release from the vaccine-maker said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8mnwCtJ
via IFTTT